The FDA has given the go-ahead to a new migraine treatment made by Eli Lily and Co.
According to the company, the drug, Reyvow, can help resolve acute migraine symptoms within two hours.
Eli Lily gained rights to the drug when it acquired CoLucid Pharmaceuticals for $960 million in 2017. Although Reyvow is entering an increasingly crowded market for migraine treatments, it is the first centrally penetrant, selective serotonin (5-HT)1F receptor agonist to win FDA approval for migraines.
The U.S. Drug Enforcement Agency is reportedly evaluating the medication as a potential controlled substance. After it receives its DEA classification, Reyvow will be ready for a commercial roll-out.
Lily has not set a price for Reyvow.
Read the Reuters report.